Amphastar Pharmaceuticals (AMPH) Debt/Assets Ratio: History & Chart

Amphastar Pharmaceuticals, Inc.(AMPH)

Drug Manufacturers - Specialty & Generic · Rancho Cucamonga, CA

$25.37-0.06 (-0.24%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Rancho Cucamonga, CA

1,976 employees

www.amphastar.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Yongfeng Zhang

View full financials

AMPH Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

39.47%

DEBT TO ASSETS RATIO AVG TTM

40.28%

DEBT TO ASSETS RATIO AVG 3Y

40.38%

DEBT TO ASSETS RATIO AVG 5Y

30.48%

DEBT TO ASSETS RATIO AVG 10Y

20.75%

DEBT TO ASSETS RATIO AVG 15Y

N/A

DEBT TO ASSETS RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-1.99%

CURRENT VS 3Y AVG

-2.24%

CURRENT VS 5Y AVG

+29.48%

CURRENT VS 10Y AVG

+90.22%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.13%

median of 378 covered companies

CURRENT VS SECTOR MEDIAN

+30264.08%

vs the sector median at left

NAME	MARKET CAP	DEBT TO ASSETS RATIO	TTM	3Y	5Y
Amphastar Pharmaceuticals, Inc. (AMPH)	$1.12B	39.47%	40.28%	40.38%	30.48%
Castle Biosciences, Inc. (CSTL)vs ›	$1.12B	0.07%	N/A	N/A	N/A
Bicara Therapeutics Inc. Common Stock (BCAX)vs ›	$1.14B	0.00%	N/A	N/A	N/A
Teladoc Health, Inc. (TDOC)vs ›	$1.05B	0.38%	N/A	N/A	N/A
Avalyn Pharma Inc. Common Stock (AVLN)vs ›	$1.20B	0.04%	N/A	N/A	N/A
Cronos Group Inc. (CRON)vs ›	$1.21B	0.00%	N/A	N/A	N/A
Damora Therapeutics, Inc. (DMRA)vs ›	$1.24B	0.00%	N/A	N/A	N/A
Aktis Oncology, Inc. (AKTS)vs ›	$989.05M	0.02%	N/A	N/A	N/A
Cullinan Therapeutics, Inc. (CGEM)vs ›	$985.79M	0.01%	N/A	N/A	N/A
CeriBell, Inc. (CBLL)vs ›	$943.26M	0.13%	N/A	N/A	N/A

NAME

MARKET CAP

DEBT TO ASSETS RATIO

TTM

Amphastar Pharmaceuticals, Inc. (AMPH)

$1.12B

39.47%

40.28%

40.38%

30.48%

Castle Biosciences, Inc. (CSTL)vs ›

$1.12B

0.07%

N/A

Bicara Therapeutics Inc. Common Stock (BCAX)vs ›

$1.14B

0.00%

N/A

Teladoc Health, Inc. (TDOC)vs ›

$1.05B

0.38%

N/A

Avalyn Pharma Inc. Common Stock (AVLN)vs ›

$1.20B

0.04%

N/A

Cronos Group Inc. (CRON)vs ›

$1.21B

0.00%

N/A

Damora Therapeutics, Inc. (DMRA)vs ›

$1.24B

0.00%

N/A

Aktis Oncology, Inc. (AKTS)vs ›

$989.05M

0.02%

N/A

Cullinan Therapeutics, Inc. (CGEM)vs ›

$985.79M

0.01%

N/A

CeriBell, Inc. (CBLL)vs ›

$943.26M

0.13%

N/A

Debt to Assets Ratio FAQ

What is the debt to assets ratio for Amphastar Pharmaceuticals, Inc. (AMPH)?

The debt to assets ratio for AMPH stock is 39.47%.

Is Amphastar Pharmaceuticals, Inc.'s debt to assets ratio high or low?

The debt to assets ratio of 39.47% is 29% above its 5-year average of 30.48%, near the high end of its 5-year range (9.96%–43.54%).

What is the TTM average debt to assets ratio for Amphastar Pharmaceuticals, Inc. (AMPH)?

The TTM average debt to assets ratio for AMPH stock is 40.28%.

What is the 3Y average debt to assets ratio for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 3Y average debt to assets ratio for AMPH stock is 40.38%.

What is the 5Y average debt to assets ratio for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 5Y average debt to assets ratio for AMPH stock is 30.48%.

What is the 10Y average debt to assets ratio for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 10Y average debt to assets ratio for AMPH stock is 20.75%.

DATE	DEBT TO ASSETS RATIO
2026-06-30	39.47%
2026-03-31	41.65%
2025-12-31	40.26%
2025-09-30	39.42%
2025-06-30	40.58%
2025-03-31	40.12%
2024-12-31	41.24%
2024-09-30	40.76%
2024-06-30	41.61%
2024-03-31	39.83%
2023-12-31	41.22%
2023-09-30	43.54%
2023-06-30	38.36%
2023-03-31	13.19%
2022-12-31	13.83%
2022-09-30	14.21%
2022-06-30	14.36%
2022-03-31	14.70%
2021-12-31	15.59%
2021-09-30	16.29%
2021-06-30	9.96%
2021-03-31	10.02%
2020-12-31	10.66%
2020-09-30	10.79%
2020-06-30	10.78%
2020-03-31	11.62%
2019-12-31	11.35%
2019-09-30	11.11%
2019-06-30	11.18%
2019-03-31	11.44%
2018-12-31	9.78%
2018-09-30	10.65%
2018-06-30	11.64%
2018-03-31	10.18%
2017-12-31	10.37%
2017-09-30	11.07%
2017-06-30	10.43%
2017-03-31	8.36%
2016-12-31	8.82%
2016-09-30	9.96%
2016-06-30	10.44%
2016-03-31	10.19%
2015-12-31	10.53%
2015-09-30	11.67%
2015-06-30	11.89%
2015-03-31	12.21%
2014-12-31	11.22%
2014-09-30	12.80%
2014-06-30	13.47%
2014-03-31	12.03%
2013-12-31	9.50%
2013-09-30	9.63%
2012-12-31	0.00%

DATE

DEBT TO ASSETS RATIO

2026-06-30

39.47%

2026-03-31

41.65%

2025-12-31

40.26%

2025-09-30

39.42%

2025-06-30

40.58%

2025-03-31

40.12%

2024-12-31

41.24%

2024-09-30

40.76%

2024-06-30

41.61%

2024-03-31

39.83%

2023-12-31

41.22%

2023-09-30

43.54%

2023-06-30

38.36%

2023-03-31

13.19%

2022-12-31

13.83%

2022-09-30

14.21%

2022-06-30

14.36%

2022-03-31

14.70%

2021-12-31

15.59%

2021-09-30

16.29%

2021-06-30

9.96%

2021-03-31

10.02%

2020-12-31

10.66%

2020-09-30

10.79%

2020-06-30

10.78%

2020-03-31

11.62%

2019-12-31

11.35%

2019-09-30

11.11%

2019-06-30

11.18%

2019-03-31

11.44%

2018-12-31

9.78%

2018-09-30

10.65%

2018-06-30

11.64%

2018-03-31

10.18%

2017-12-31

10.37%

2017-09-30

11.07%

2017-06-30

10.43%

2017-03-31

8.36%

2016-12-31

8.82%

2016-09-30

9.96%

2016-06-30

10.44%

2016-03-31

10.19%

2015-12-31

10.53%

2015-09-30

11.67%

2015-06-30

11.89%

2015-03-31

12.21%

2014-12-31

11.22%

2014-09-30

12.80%

2014-06-30

13.47%

2014-03-31

12.03%

2013-12-31

9.50%

2013-09-30

9.63%

2012-12-31

0.00%

Debt to Assets Ratio: 39.47%

AMPH Debt to Assets Ratio

AMPH Average Debt to Assets Ratio Chart

AMPH Current vs Average Debt to Assets Ratio Chart

AMPH Debt to Assets Ratio Metrics

AMPH Competitors' Debt to Assets Ratio

Leverage Ratios Comparison

Debt to Assets Ratio Formula & Definition

Debt to Assets Ratio FAQ

AMPH Debt to Assets Ratio History

Related Metrics